Syncom Formulation (India)'s revenue for the
three
months ended in Sep. 2024 was ₹1,023 Mil.
Its revenue for the trailing twelve months (TTM) ended in Sep. 2024 was ₹3,251 Mil.
Syncom Formulation (India)'s Revenue per Share for the
three
months ended in Sep. 2024 was ₹1.47.
Its Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was ₹4.32.
Warning Sign:
Syncom Formulation (India) Ltd revenue per share has been in decline over the past 3 years.
During the past 12 months, the average Revenue per Share Growth Rate of Syncom Formulation (India) was 57.90% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -2.30% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 2.20% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 1.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, Syncom Formulation (India)'s highest 3-Year average Revenue per Share Growth Rate was 40.40% per year. The lowest was -33.20% per year. And the median was -0.35% per year.
Syncom Formulation (India) Revenue Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Syncom Formulation (India)'s Revenue
For the Drug Manufacturers - Specialty & Generic subindustry, Syncom Formulation (India)'s Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Syncom Formulation (India)'s Revenue Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Syncom Formulation (India)'s Revenue distribution charts can be found below:
* The bar in red indicates where Syncom Formulation (India)'s Revenue falls into.
Syncom Formulation (India) Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹3,251 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Syncom Formulation (India) Revenue Related Terms
Thank you for viewing the detailed overview of Syncom Formulation (India)'s Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Syncom Formulation (India) Ltd is in the business of pharmaceuticals. The company operates through three segments including manufacturing and dealings in Pharmaceutical drugs and formulations, Trading of commodities, and Renting of property. It manufactures and markets pharmaceutical formulation products in various dosage forms like tablets, capsules, liquids orals, liquids vials, ampoule injections and dry vial injections, dry syrups, ointments, inhalers, and Herbals. The company's product includes generic, antiviral, antidepressant, cough suppressant, electrolyte, histamine, estrogen, and much more. It generates maximum revenue through the Pharmaceutical drugs and formulations segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NSE:SYNCOMF has been successfully added to your 